Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-23
    E.g., 2018-09-23

Articles

173342 items
9:41 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the co-primary endpoint of specificity but missed the co-primary endpoint of sensitivity in a Phase III trial to detect low-grade...
9:39 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Viking's VK2809 meets in Phase II for NAFLD

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year...
9:39 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Braeburn’s CAM2038 meets in Phase III for chronic low back pain

Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said CAM2038 met the primary endpoint in the Phase III HS-16-555 trial to treat moderate to severe chronic low back pain in patients previously on long-term daily opioid therapy....
9:38 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in...
9:38 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial showing that anti-PD-1 antibody sintilimab (IBI308) plus Alimta...
9:38 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation...
9:37 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Roxadustat meets in Phase III for CKD patients with anemia not on dialysis

Astellas Pharma Inc. (Tokyo:4503) said roxadustat (ASP1517, FG-4592) met both primary endpoints in the Phase III ALPS trial to treat anemia in patients with chronic kidney disease (CKD) who were not receiving dialysis. On the primary...
9:37 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Allergan to acquire botulinum neurotoxin play Bonti

Allergan plc (NYSE:AGN) will acquire Bonti Inc. (Newport Beach, Calif.) for $195 million up front. Bonti shareholders are also eligible for undisclosed commercial milestone payments. Allergan and Bonti declined to disclose details. In May, Allergan CEO...
9:37 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Mersana gets green light to resume ADC trial, but new dosing may slow progress

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 on Sept....
9:36 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is eligible...

Pages